The choice between venetoclax (ven) plus rituximab (R) and ibrutinib depends on medical factors outlined in Table 1, as well as considerations that include: longer-term follow-up data with ibrutinib at present, good data on ven response after progression with ibrutinib compared with few data on the reverse, potential for time-limited therapy with ven vs indefinite therapy with ibrutinib, more intense monitoring early on for ven, fewer long-term adverse effects with ven, and patient preference. AE, adverse event; alloSCT, allogeneic stem-cell transplantation; CAR-T, chimeric antigen receptor T cell; idela, idelalisib; IWCLL, International Workshop on Chronic Lymphocytic Leukemia; PD, progressive disease.